Company Overview
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Recent Developments
- Dec 2025 Revenue of $6.94M (-23.2% YoY); net profit $-212.39M.
- Trailing 12 Months Year-on-year growth — revenue -23.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -23.23% |
Stock Price Performance
| 1 Year: | +79.72% |
| 6 Months: | -23.64% |
| 3 Months: | -20.33% |
| 1 Month: | -19.47% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)35.88 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 39.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IMNM Immunome, Inc. R2KR3KPHARMA | 17.99 | -7.11 | $2.04B | 0.00% | -35.12% | -64.03% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 2.36M | 4.26M | 3.56M | 1.03M | 2.36M | - | - | 2.93M | 4.01M | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.56M | 50.49M | 60.14M | 72.86M | 59.33M | - |
| Operating Income | -2.72M | -2.65M | -2.71M | -2.82M | -3.90M | -5.74M | -7.72M | -11.65M | -8.93M | -8.53M | -4.47M | -5.77M | -4.63M | -132.30M | -40.01M | - | - | -44.64M | -46.48M | -60.14M | -72.86M | -59.33M | -78.14M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -43.91M | -45.76M | -59.41M | -72.08M | -58.58M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -41.64M | -43.40M | -57.46M | -69.90M | -53.84M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.74M | -2.68M | -2.71M | -8.38M | -3.90M | -5.24M | -7.72M | -11.65M | -8.92M | -8.53M | -4.27M | -5.56M | -4.34M | -129.49M | -36.12M | - | - | -41.64M | -43.40M | -57.46M | -69.90M | -53.84M | -73.13M |
| Diluted EPS | - | - | - | - | -0.37 | -0.46 | -0.65 | -0.96 | -0.74 | -0.75 | -0.35 | -0.46 | -0.36 | -2.51 | -0.60 | -0.78 | - | -0.52 | -0.50 | -0.65 | - | -0.48 | -0.65 |
| R&D Expense | 2.23M | 2.12M | 1.89M | 1.64M | 1.98M | 3.23M | 4.51M | 8.08M | 5.72M | 5.22M | 3.91M | 5.72M | 3.82M | 15.37M | 29.08M | 37.20M | - | 36.87M | 40.45M | 49.19M | - | 46.38M | 59.88M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 14.02M | 9.04M | 6.94M |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 36.90M | 42.75M | 162.50M | 231.05M |
| Operating Income | -10.35M | -12.26M | - | -36.90M | -28.73M | -153.46M | -224.11M |
| EBITDA | - | - | - | -36.27M | -28.00M | -151.35M | -221.16M |
| Interest Expense | - | - | 10.00K | - | - | - | - |
| Pretax Income | - | - | - | -36.90M | -106.81M | -292.96M | -212.39M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -10.44M | -17.84M | - | -36.90M | -106.81M | -292.96M | -212.39M |
| Diluted EPS | - | -5.26 | - | -3.09 | -5.38 | -5.00 | -2.43 |
| R&D Expense | 8.82M | 7.49M | 14.11M | 23.27M | 23.09M | 129.54M | 177.29M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 5.06M | 44.52M | - | 24.05M | 148.54M | 240.24M | 683.19M |
| Current Assets | - | - | - | - | 22.65M | 144.70M | 221.34M | 660.78M |
| Cash & Equivalents | - | 2.54M | 39.77M | - | 20.32M | 98.68M | 143.35M | 653.48M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | 0 | 847.00K | - | - | - |
| Total Liabilities | - | 1.80M | 3.18M | - | 7.39M | 28.66M | 59.08M | 48.84M |
| Current Liabilities | - | 1.67M | 3.04M | - | 7.33M | 21.83M | 54.31M | 44.99M |
| Long Term Debt | - | - | 134.00K | - | - | - | - | - |
| Total Debt | - | - | - | - | 291.00K | 1.65M | 4.83M | 3.85M |
| Total Equity | -25.20M | -35.63M | 41.34M | - | 16.65M | 119.88M | 181.16M | 634.34M |
| Shares Outstanding | - | - | - | - | 12.13M | 43.25M | 64.46M | 113.13M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.60M | -12.13M | -18.23M | -28.69M | -7.57M | -110.79M | -190.92M |
| Investing Cash Flow | -233.00K | -586.00K | -79.00K | -248.00K | -30.48M | -85.06M | 60.80M |
| Financing Cash Flow | 10.77M | 49.94M | 27.77M | 32.00K | 116.41M | 240.53M | 640.36M |
| Capital Expenditure | -233.00K | -586.00K | -79.00K | -248.00K | -831.00K | -7.17M | -9.69M |
| Free Cash Flow | -9.83M | -12.72M | -18.30M | -28.94M | -8.40M | -117.97M | -200.60M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -204.9% | -1,697.3% | -3,228.8% |
| Net Margin % | - | - | - | - | -761.9% | -3,240.4% | -3,060.0% |
| ROE % | 29.3% | -43.1% | - | -221.6% | -89.1% | -161.7% | -33.5% |
| ROCE % | -304.8% | -29.6% | - | -220.8% | -22.7% | -82.5% | -35.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 17.32% | 19.68M | $384.68M |
| 2 | FMR, LLC | 14.96% | 16.99M | $332.11M |
| 3 | Blackrock Inc. | 7.75% | 8.81M | $172.15M |
| 4 | State Street Corporation | 4.84% | 5.49M | $107.42M |
| 5 | Wellington Management Group, LLP | 4.59% | 5.21M | $101.86M |
| 6 | Redmile Group, LLC | 4.32% | 4.91M | $96.02M |
| 7 | Primecap Management Company | 4.03% | 4.58M | $89.57M |
| 8 | Vanguard Capital Management LLC | 4.01% | 4.55M | $88.98M |
| 9 | Driehaus Capital Management, LLC | 3.83% | 4.35M | $84.97M |
| 10 | Enavate Sciences Gp, LLC | 3.18% | 3.61M | $70.65M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMNM
Immunome, Inc. Estimates – NASDAQ:IMNM - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE9FZmx5NFNjejdxZ2JBOXdqNmp3YVNWWXZORmh5QjJ5alY5Yk8tbmhjNkFLdUZ4RUs3UVdPczhLTTZncnY1eUwyOGhvcVdNeGV2dHBETkI3cWRNdWxURWNlM0lrUnh1QlItcGtCdE84bHhWczBZQ0FJdg?oc=5" target="_blank">Immun…
IMNM Apr 2027 24.000 call (IMNM270416C00024000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE1DQVgzbjZtalBCVDVscU9hR05yVHlweGdVRy1IT1RJR3NZM19CUnAyZWxWSHZkbFJ5MXkxVjg1RlNBSnk5VEh3ZlZzZEFwM1RkZDJUZHdtR3JhSG1sWlVDMkNhdmFjdw?oc=5" target="_blank">IMNM Apr 2027 24.000 call (IM…
IMNM Nov 2026 20.000 put (IMNM261120P00020000) Stock Historical Prices & Data - Yahoo Finance - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE5CWkl2MUxVNWdtU3pHOXEzakoyU09TRXZJRkNaV3B0WkpNVi1oQ1d3VFUzMTVaSXp3eGdlbDVsakJ0dm1BbU10aDE5SGV5YmE5OHlONHNrQVBxSnItMG53U0l5dXJWbHdqQjNGR1NvOWg?oc=5" target="_blank">IMNM Nov 2026 20…
IMNM Nov 2026 23.000 put (IMNM261120P00023000) stock historical prices and data - Yahoo Finance Singapore
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE1RcEZRbDRVX0hmTW9CekozNEtjZFdpaU11dzZGZUtrVkd1bllNcXpDbmg0eDBqcTlBMXdJbmlWUk9RZVA3OEQ3cVRjbGdReGlWRHpfZjhDTFNLSE9MXzdPbnhzOHVENHhYdkVwc3VZamY?oc=5" target="_blank">IMNM Nov 2026 23…
IMNM Nov 2026 22.000 put (IMNM261120P00022000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE1fU05UZHlITkdJSWh5WkN5MzRSbExkN3kxdHVIMWE3TWJFZVA5UXBZYXZ2M3NEcnhyYnRDNTlEb1NoOThOY05PWHRUbzNiMXFQczNIaXMzSi0tcWtjeHFUVGtXOVV3Zw?oc=5" target="_blank">IMNM Nov 2026 22.000 put (IMN…
IMNM Nov 2026 20.000 put (IMNM261120P00020000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTFAwY3BZZUJHVHMwYVd6Z24xNnllZ2lsanZiTUNicExrY2ExUDZzMXJyeUVteWU0cklrN0wwbzgzcThFM0RQTjBfeGZQRUpsaHBaaUJpRHo4N2xRUnlJRDBzOW10SVh1QQ?oc=5" target="_blank">IMNM Nov 2026 20.000 put (IMN…
IMNM — Frequently Asked Questions
What is the current share price of Immunome, Inc. (IMNM)?
As of 2026-10-23 16:27 PDT, Immunome, Inc. (IMNM) trades at $17.99 on NasdaqCM. Its 52-week range is $8.99 to $29.82.
What is the market capitalisation of IMNM?
Immunome, Inc. (IMNM) has a market capitalisation of $2.04B on NasdaqCM.
What is the P/E ratio of IMNM?
IMNM trades at a trailing price-to-earnings (P/E) ratio of -7.11. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 5.18.
What is the return on equity (ROE) of IMNM?
IMNM has a return on equity (ROE) of -64.03%. Its return on capital employed (ROCE) is -35.12%.
Is IMNM a good stock to buy?
This page provides a data-driven analysis of Immunome, Inc. (IMNM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.